IRadimed Corp. (IRMD)

IRadimed Corp. reported record fourth-quarter and full-year 2025 financial results, increasing its regular quarterly cash dividend to $0.20 per share and approving a special cash dividend of $0.50 per share. The company initiated shipments of the next-generation MRidium® 3870 IV Infusion Pump System, with a full U.S. rollout anticipated in the first quarter of 2026. Joe Kiani was appointed to the Board of Directors, effective September 2, 2025. The company participated in the 38th Annual Roth Conference on March 16, 2026. Over the last 12 months, the stock price increased by 97.50%, with a year-to-date return of 5.67% as of March 17, 2026. Insider selling activity was observed from John Glenn, James Hawkins, and Monty Allen between November 2025 and February 2026.

IRadimed Corp. stock has shown some seasonal patterns, though with a "Poor" consistency score. November has historically been the strongest month for IRMD, while February has tended to be the weakest month. The company's revenue is primarily dependent on the market for MRI-compatible patient monitors and IV pumps.

IRadimed Corp. is a medical device company specializing in MRI-compatible products, operating in the Healthcare sector, specifically in Healthcare Equipment & Supplies and Medical Equipment & Supplies. The company develops, manufactures, markets, and distributes MRI-compatible IV infusion pump systems and patient vital signs monitoring systems, along with related accessories, disposables, and services. Its major products include the MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump Systems, designed for safe delivery of medications during MRI procedures. The 3880 MRI Compatible Patient Vital Signs Monitoring System features non-magnetic components for accurate monitoring during MRI procedures. The 3600 FMD1 Ferromagnetic Detection Device is used for ferromagnetic detection at MRI screening room entrances. Other related products include non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.

Headquartered in Orlando, Florida, IRadimed Corp. sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. Domestic sales constituted 85% of total revenue for the nine months ended September 30, 2025. The company markets its products in approximately 80 countries globally, with key geographies including the U.S., Europe, and Japan. Its international distribution network spans the Americas, Europe, the Middle East, Africa, Asia, and Oceania.

IRadimed Corp. has maintained a strong brand reputation, being named to Forbes' list of America's Most Successful Small-Cap Companies for 2024 and TIME's List of America's Growth Leaders for 2026. The FDA granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System in May 2025. The company consistently reports record revenues and strong financial results. Analysts generally hold a positive sentiment towards IRadimed, and the stock has received a strong momentum grade. IRadimed is recognized as a leader and the only known provider of non-magnetic IV infusion pump systems specifically designed for MRI procedures.

IRadimed Corp. has a significant institutional ownership base, with 222 institutional owners holding a total of 7,253,648 shares as of March 31, 2026. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Renaissance Technologies Llc, and others. Roger Susi, Founder, Chairman, CEO & President, owns 34.9% of the shares.